Injective (INJ) is currently trading at $4.34, experiencing a 4.97% increase in the last 24 hours. The daily trading range has been relatively tight, with a high of $4.39 and a low of $4.12, reflecting a 0.27% volatility in the price movement.

The trading volume stands at approximately $65.27 million, with a volume-to-market cap ratio of 15.01%, indicating healthy market activity. Technical indicators show short-term upward momentum; the 8 SMA is at $4.25 with a 2.01% increase, while the 21 SMA shows a stronger growth of 2.44%, suggesting bullish sentiment in the immediate term.

The Relative Strength Index (RSI) readings are also positive, with the 1-hour RSI at 57 and the 7-day RSI at 58, which indicates that INJ is neither overbought nor oversold. Over the past 30 days, the price has surged by 44.06%, supported by a solid upward trend reflected in the 14-day price change of 18.12%.

Injective's all-time high of $52.62 was reached on March 14, 2024, suggesting significant long-term potential. However, the current price remains substantially below that level, providing a favorable entry point for investors looking to capitalize on future price appreciation.

Given the positive short-term momentum, healthy volume, and favorable RSI indicators, the outlook for Injective is bullish. Therefore, I recommend a Buy rating on INJ, as the asset shows strong potential for upward movement in the near term.